Oric Pharmaceuticals Replaces ATM Program with New $200M Offering, Discloses $139.7M Already Sold

summarizeSummary

Oric Pharmaceuticals has replaced its existing ATM program with a new $200 million offering, having already sold $139.7 million under the previous program, securing capital for ongoing clinical development.

check_boxKey Events

• ATM Program Replaced and Expanded

  Oric Pharmaceuticals filed a new prospectus supplement for an At-The-Market (ATM) offering, authorizing the sale of up to $200.0 million in common stock, replacing the prior 2024 program.

• Significant Prior Sales Disclosed

  The company disclosed that it had already sold approximately $139.7 million in shares under the previous 2024 ATM program as of February 23, 2026.

• Funding Clinical Pipeline

  This capital raise is crucial for funding the company's clinical development, especially as its oncology candidates advance towards Phase 3 trials following recent positive Phase 1b data.

auto_awesomeAnalysis

This 8-K provides critical context to Oric Pharmaceuticals' capital strategy, detailing the replacement of its existing At-The-Market (ATM) offering program with a new $200 million facility. Importantly, the filing reveals that the company had already sold a substantial $139.7 million under the previous ATM, indicating a consistent reliance on this financing method. The new $200 million program, while dilutive, is essential for extending the company's cash runway and funding the continued advancement of its oncology pipeline, particularly given the positive Phase 1b clinical data reported concurrently. Investors should monitor the pace of future share sales and their impact on outstanding share count.